athenahealth buys SaaS provider for $22.3M

Jeff Byers | | Health Exec | Economics
Watertown, Mass.-based athenahealth, a provider of Internet-based business services for physician practices, has signed a definitive agreement to acquire Anodyne Health Partners, which develops Software-as-a-Service (SaaS) business applications for healthcare providers. The transaction, including a cash payment of $22.3 million, is expected to close this month.

Anodyne currently services large and enterprise medical group clients with a proprietary Web-based business intelligence software platform, Anodyne Intelligence, and related services, athenahealth said. The platform allows an organization to view all facets of its revenue cycle and to access and extract critical operational and administrative information from various data systems.

Terms of the merger agreement include a cash payment of $22.3 million with the potential for additional consideration of up to $7.7 million, based on the achievement of certain business and financial milestones. The Alpharetta, Ga.-based Anodyne will operate as a separate unit of athenahealth with its own brand identity, according to athenahealth.

Jeff Byers

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.